Showing results (1431-1440 of 10,441) with videos related to
Sort By:
Pageof 1,045
AIDS (London, England)|February 16, 2012
Social and structural factors associated with HIV disease progression among illicit drug users: a systematic reviewMichael-John S Milloy, Brandon D L Marshall, Thomas Kerr, et al.AIDS (London, England)|February 16, 2012
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAriane van der Straten, Lut Van Damme, Jessica E Haberer, et al.AIDS (London, England)|February 4, 2012
Novel clinical trial designs for the development of new antiretroviral agentsNina Mani, Jeffrey Murray, Roy M Gulick, et al.AIDS (London, England)|February 4, 2012
Pathogen prevalence may determine maintenance of antigen-specific T-cell responses in HIV-infected individualsAlexandra Schuetz, Jan Dirks, Urban Sester, et al.AIDS (London, England)|January 12, 2012
Immune reconstitution inflammatory syndrome: incidence and implications for mortalityRichard M Novak, James T Richardson, Kate Buchacz, et al.AIDS (London, England)|March 24, 2012
Response to antiretroviral therapy: improved survival associated with CD4 above 500 cells/μlDavid Maman, Mar Pujades-Rodriguez, Sarala Nicholas, et al.AIDS (London, England)|March 24, 2012
When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?Phillip J Read, Sundhiya Mandalia, Palwasha Khan, et al.AIDS (London, England)|March 24, 2012
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settingsJohn A Bartlett, Heather J Ribaudo, Carole L Wallis, et al.AIDS (London, England)|April 5, 2012
An overview of intracellular interactions between immunodeficiency viruses and their hostsPaul D BieniaszAIDS (London, England)|April 21, 2012
Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individualsLivio Azzoni, Andrea S Foulkes, Cynthia Firnhaber, et al.Pageof 1,045